793695-88-2 Usage
Uses
Used in Pharmaceutical Industry:
(2-Chloro-5-iodophenyl)methanamine hydrochloride is used as a chemical intermediate for the synthesis of various active pharmaceutical ingredients and other bioactive molecules. Its unique structure and reactivity make it a valuable building block in the development of new drugs and pharmaceutical formulations.
Used in Organic Synthesis:
(2-Chloro-5-iodophenyl)methanamine hydrochloride is used as a reagent in various organic synthesis processes. Its unique structure and reactivity allow it to be used in the synthesis of complex organic compounds, contributing to the advancement of organic chemistry and the development of new chemical entities.
Used in Drug Discovery and Development:
(2-Chloro-5-iodophenyl)methanamine hydrochloride is used as a potential candidate in drug discovery and development. Its unique properties and reactivity make it a promising compound for the development of new therapeutic agents and pharmaceutical formulations.
Check Digit Verification of cas no
The CAS Registry Mumber 793695-88-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,3,6,9 and 5 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 793695-88:
(8*7)+(7*9)+(6*3)+(5*6)+(4*9)+(3*5)+(2*8)+(1*8)=242
242 % 10 = 2
So 793695-88-2 is a valid CAS Registry Number.
793695-88-2Relevant academic research and scientific papers
PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS
-
Page/Page column 28, (2010/10/20)
Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.
